Shelly Guyer - Veracyte CFO

VCYT Stock  USD 22.16  0.44  2.03%   

CFO

Ms. Shelly D. Guyer is no longer Chief Financial Officer of the Company effective from December 6 2016. She Principal Accounting Officer Secretary at Veracyte Inc. Ms. Guyer joined Veracyte as Chief Financial Officer in April 2013 bringing over 25 years of experience in the finance and life science industries. Prior to Veracyte she served as CFO and Executive Vice President of Finance and Administration at iRhythm Technologies a medical device and services company. Prior to that she served on the management team and as Vice President of Business Development and Investor Relations at Nuvelo a biotechnology company since 2015.
Age 54
Tenure 9 years
Professional MarksMBA
Address 6000 Shoreline Court, South San Francisco, CA, United States, 94080
Phone650 243 6300
Webhttps://www.veracyte.com
Guyer began her business career at J.P. Morgan Securities and its predecessor companies, where for over 17 years she held various positions, including Principal and VP of Health Care Banking for the West Coast; as a manager in the Investment Banking Division; and as VP with Hambrecht & Quist Venture Partners. She received an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley, and a B.A. from Princeton University.

Veracyte Management Efficiency

Return On Capital Employed is likely to drop to -0.01 in 2024. Return On Assets is likely to drop to -0.07 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 19.6 M in 2024. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 12.63 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Veracyte has a current ratio of 4.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Veracyte until it has trouble settling it off, either with new capital or with free cash flow. So, Veracyte's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veracyte sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veracyte to invest in growth at high rates of return. When we think about Veracyte's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

CFO Age

Didier HirschAgilent Technologies
66
Sharon MalkaMediwound
45
The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. Veracyte (VCYT) is traded on NASDAQ Exchange in USA. It is located in 6000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 815 people. Veracyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Veracyte Leadership Team

Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
Shelly Guyer, CFO, Principal Accounting Officer and Member of Non-Management Equity Award Committee
Brian Atwood, Chairman of the Board
Neil Barth, Chief Medical Officer
Christopher Hall, COO
Mark Ho, Principal Accounting Officer
Robert Epstein, Director
Kevin Gordon, Director
Karin Eastham, Director
Evan Jones, Director
Keith Kennedy, CFO
Corinne Danan, Senior President
Tina Nova, Director
Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee
John Bishop, Director
Angie McCabe, IR Contact Officer
Rebecca Chambers, Executive CFO
Jonathan Wygant, VP Officer
Jackie Cossmon, IR Contact Officer
Beverly CPA, VP Controller
Julie Brooks, Executive Vice President General Counsel, Secretary
Steven French, Senior Officer
Fred Cohen, Director
Robert Brainin, Executive Officer
John Leite, Chief Business
Annie McGuire, Sr Counsel
Tracy Morris, VP Communications
Jesse Treu, Director
Phillip MD, Chief Officer
John Hanna, Chief Commercial Officer
Karen Possemato, Communications Marketing
Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer
Marc Stapley, CEO Director

Veracyte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Veracyte Stock analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.02)
Revenue Per Share
4.97
Quarterly Revenue Growth
0.223
Return On Assets
(0.01)
Return On Equity
(0.07)
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.